Completed
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
NCT05314231
- Conditions
- Autoimmune Diseases, Chronic Disease, Connective Tissue Diseases, +31 more
- Locations
-
- Clinical Trial Site 2 Anyang-si, Gyeonggi-do, South Korea
- Clinical Trial Site 1 Seoul, South Korea